SANGAMO THERAPEUTICS INC
SGMO
SGMO was delisted on the 4th of May, 2026.
118 hedge funds and large institutions have $241M invested in SANGAMO THERAPEUTICS INC in 2017 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 29 increasing their positions, 40 reducing their positions, and 22 closing their positions.
90% more capital invested
Capital invested by funds: $127M → $241M (+$114M)
57% more call options, than puts
Call options by funds: $3.91M | Put options by funds: $2.49M
0.56% more ownership
Funds ownership: 58.69% → 59.26% (+0.56%)
9% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 22
6% less funds holding
Funds holding: 126 → 118 (-8)
28% less repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 40
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$22.5M |
| 2 |
CC
Casdin Capital
New York
|
+$3.41M |
| 3 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
+$3.19M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
+$2.01M |
| 5 |
BBA
Baker Bros. Advisors
New York
|
+$1.91M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$2.16M |
| 2 |
NC
Nexthera Capital
New York
|
-$1.53M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$1.12M |
| 4 |
Renaissance Technologies
New York
|
-$982K |
| 5 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$787K |
SGMO Hedge Fund Activity: Q1 2017 in Review
118 of the 4,018 institutional investors tracked by Wall St. Rank reported a position in SANGAMO THERAPEUTICS INC (SGMO) for Q1 2017, worth a combined $241M — up 90% from $127M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of SGMO and 20 opened new positions — a net loss of 2 holders — while 40 trimmed existing stakes and 29 added.
The largest buyer was BlackRock, adding an estimated $22.5M. The largest seller was OrbiMed, exiting entirely with an estimated $2.16M sold.
- 118 institutional investors held SANGAMO THERAPEUTICS INC (SGMO) as of Q1 2017, down from 126 in Q4 2016.
- Funds reported $241M of SANGAMO THERAPEUTICS INC stock for Q1 2017, up 90% quarter-over-quarter.
- 20 funds opened new SANGAMO THERAPEUTICS INC positions in Q1 2017 and 22 closed out, a net change of -2 holders.
- The largest SANGAMO THERAPEUTICS INC buyer in Q1 2017 was BlackRock, an estimated $22.5M added.
- The largest SANGAMO THERAPEUTICS INC seller in Q1 2017 was OrbiMed, an estimated $2.16M sold.
Based on aggregated 13F filings for Q1 2017.